Best Youth Sports Grants in Guam

The FY26 Melanoma Research Program Team Science Award promotes collaborative, hypothesis-driven research to enhance melanoma care. This funding supports multidisciplinary teams of two to three Principal Investigators (PIs) to tackle complex challenges in melanoma. With approximately $18.9M available, the program aims to fund nine projects with a maximum of $2.1M per award over three years. Awards will be made by September 30, 2027, using FY26 funds that expire on September 30, 2032.

The FY26 Military Burn Research Program (MBRP) Technology/Therapeutic Development Award (TTDA) aims to translate promising preclinical findings into burn products for clinical use in challenging environments. This award supports the development of both tangible products, like medical devices, and knowledge products that enhance health outcomes. A new Mentorship Option encourages collaboration between experienced researchers and junior scientists, fostering the next generation of leaders in military burn care research.

The FY26 Military Burn Research Program (MBRP) Discovery Award aims to support groundbreaking research in combat-relevant burn care. This award encourages innovative and exploratory studies that provide new insights and foundational data for future clinical research. The focus is on novel approaches that lay the groundwork for scientific advancements and product development in burn care, ensuring robust preliminary data generation for subsequent research initiatives.

The DoW Military Burn, Patient-Centered Research Award aims to enhance the implementation of burn care research into clinical practice for military settings. The FY26 program supports clinical trials and research that directly benefit burn patients in resource-limited environments, fostering collaborations between experienced researchers and junior scholars. This initiative addresses critical gaps in combat burn care, ensuring effective interventions and guidelines are developed and utilized in operational battlespaces.

The DoW Prostate Cancer Idea Development Award for fiscal year 2026 supports innovative research ideas that address the Prostate Cancer Research Program's overarching challenges. This award emphasizes new investigators within 10 years of their terminal degree, encouraging collaboration with experienced researchers in the field. By fostering unique approaches to prostate cancer research, the program aims to make significant contributions to advancing understanding and treatment of this disease.

The NIH Independent Scientist Award (K02) supports the development of outstanding scientists by providing three to five years of salary support and protected time for newly independent researchers. This funding opportunity is specifically for applicants proposing research that does not involve leading an independent clinical trial, allowing them to gain experience in trials led by others. Key deadlines for applications span from June 2024 to February 2027.

The NIH Independent Scientist Award (K02) aims to support the development of independent scientists and enhance their research capabilities. This award offers salary support and protected time for three to five years, specifically for those leading independent clinical trials or feasibility studies. Applicants must demonstrate a need for focused research to advance their careers. Key deadlines for applications span from June 2024 to February 2027, catering to various submission types including standard and AIDS-related grants.

The Mentored Clinical Scientist Research Career Development Award (K08) supports individuals with clinical doctoral degrees to pursue intensive research training. This program focuses on developing skills in biomedical and behavioral research, addressing national health-related research needs. Key deadlines for applications span from June 2024 to February 2027, with specific dates for standard, renewal, and AIDS-related grants, ensuring that qualified candidates have ample opportunity to apply and advance their research careers.

The Mentored Clinical Scientist Research Career Development Award (K08) supports individuals with clinical doctoral degrees to develop their research careers in biomedical and behavioral fields. This program emphasizes a structured mentoring approach, aiming to address the nation's health-related research needs. Key application deadlines include June 12, 2024, and October 12, 2024, among others, providing opportunities for both new and renewal submissions.

The NIH Mentored Clinical Scientist Research Career Development Award (K08) aims to develop the research careers of individuals with clinical doctoral degrees. This program provides essential support and protected time for intensive, supervised research experiences in biomedical and behavioral fields, including translational research. Important deadlines for applications span from June 2024 to February 2027, accommodating various grant types, including standard and AIDS-related applications.

The NIH Mentored Research Scientist Development Award (K01) supports early-career scientists with up to five years of protected time for intensive research training in biomedical, behavioral, or clinical sciences. This award is tailored for those pursuing independence in research and is particularly beneficial for individuals transitioning fields or returning from a hiatus. Importantly, applicants must not lead independent clinical trials but may participate in trials overseen by mentors.

The NIH Mentored Research Scientist Development Award (K01) aims to support emerging scientists by providing protected time for career development in biomedical, behavioral, or clinical sciences. This award, effective for three to five years, encourages research independence and may be beneficial for those transitioning fields or returning from a hiatus due to personal circumstances. Deadlines for applications vary, with important dates set for standard, renewal, and AIDS-related submissions.

The Mentored Quantitative Research Development Award (K25) aims to attract researchers with quantitative science backgrounds to NIH-relevant studies. It provides support and protected time for professionals to integrate their expertise in areas like mathematics and statistics with health research. Notably, it does not support independent clinical trials, focusing instead on collaborative experiences under mentorship. The application process involves specific deadlines for submissions, including standard, renewal, and AIDS-related grants, encouraging diverse participation in significant health research.

The Mentored Quantitative Research Development Award (K25) aims to engage skilled professionals in NIH-relevant research, enhancing their expertise in addressing health-related issues. This award supports individuals with backgrounds in quantitative sciences and engineering, providing them with dedicated time for supervised research and study. Key application deadlines span from June 2024 to February 2027, emphasizing the program's commitment to fostering innovative research in health and disease.

The Mentored Quantitative Research Development Award (K25) aims to attract researchers in quantitative science and engineering to focus on NIH-relevant health research. This award provides protected time for supervised study and research, allowing professionals from fields like mathematics, statistics, and engineering to integrate their expertise into health-related studies. The K25 is specifically for lead investigators of independent clinical trials or related studies, fostering innovation in clinical research and career development.

The FY26 Pancreatic Cancer Research Program (PCARP) Idea Development Award promotes innovative, high-risk research aimed at significant advancements for pancreatic cancer outcomes. This award supports projects with preliminary data, focusing on impactful discoveries. It features a Partnering Principal Investigator option, enhancing funding for collaborations between experienced mentors and early-career researchers. All applications must align with the FY26 PCARP Focus Areas, ensuring relevance and potential for transformative results in pancreatic cancer research.

The FY26 Pancreatic Cancer Research Program (PCARP) Translational Research Partnership Award encourages collaboration among clinicians and scientists to expedite the clinical application of innovative pancreatic cancer research. A minimum of two Principal Investigators is required, with one designated as the Initiating PI. This award supports preliminary data collection and various research methodologies, excluding large-scale clinical trials, to enhance pancreatic cancer understanding and treatment.

The FY26 Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award supports innovative research aimed at advancing therapies for ALS. It focuses on projects that have demonstrated proof-of-concept efficacy and require lead compounds. The award emphasizes the development of mechanism-specific biomarkers to enhance trial design and patient selection, ensuring that therapeutic approaches are effective and efficient. Collaboration with experienced ALS researchers is encouraged for those with limited experience.

The FY26 Amyotrophic Lateral Sclerosis Research Program Therapeutic Idea Award supports innovative ideas for ALS drug discovery. This award encourages high-risk, high-gain research that is hypothesis-driven and aims to generate preliminary data for future therapeutic investigations. Applications should highlight potential impact and innovation, with the possibility of achieving results without prior data. The focus is on a strong approach rather than preliminary findings.

The FY26 DoW Pancreatic Cancer Research Program Focused Pilot Award aims to drive innovative and impactful research in pancreatic cancer, enhancing patient quality of life. This award encourages the development of preliminary data to support future clinical or real-world applications. While allowing for clinical research studies, it does not permit clinical trials or preclinical animal studies, ensuring a strong patient-centered approach in its research focus.

The FY26 Amyotrophic Lateral Sclerosis Research Program's Pilot Clinical Trial Award aims to accelerate clinical trials that can significantly impact ALS treatment and management. Focus areas include biomarker-driven interventions and improvements in clinical care. Trials must begin within 12 months of the award and incorporate community collaboration and a detailed regulatory strategy. This award emphasizes the importance of therapeutic interventions and a transition plan for advancing study outcomes beyond the funded work.

The FY26 Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) aims to enhance clinical trials for ALS by developing and validating clinical outcomes and biomarkers. This funding opportunity encourages innovative projects that may focus on specific therapies, ALS subtypes, or digital health measures. Collaboration with the ALS community is essential to ensure that research is relevant and informed by lived experiences.

The FY26 Breast Cancer Research Program (BCRP) Breakthrough Award Level 4 supports innovative research with the potential for significant breakthroughs in breast cancer. Applications must address key BCRP challenges or justify exceptions, focusing on impactful solutions. This program mandates clinical trials and requires participation from breast cancer consumer advocates. The funding supports single or partnered Principal Investigators, ensuring comprehensive submission processes to avoid administrative withdrawal.

The DoW Ovarian Cancer Academy Early-Career Investigator Award supports junior faculty in conducting innovative ovarian cancer research. Established in FY09, this unique virtual academy fosters mentorship, collaboration, and networking among Early-Career Investigators (ECIs) and their mentors. Participants engage in monthly webinars and annual workshops, enhancing their research skills while contributing to impactful studies in ovarian cancer. The program aims to cultivate a new generation of highly productive researchers in this critical field.

The Ovarian Cancer Clinical Trial Academy (OCCTA) supports Early-Career Investigators (ECIs) in clinical trial research aimed at effective ovarian cancer treatments. It provides essential mentoring, networking, and skill development needed for executing clinical trials. The FY26 funding will specifically support translational research and early-phase trials, requiring preliminary data and a commitment of at least 25% effort from the ECI. Mentorship is vital, with a focus on experienced clinical trialists guiding ECIs.

The DoW Ovarian Cancer Clinical Trial Award, funded by the U.S. Army Medical Command, aims to accelerate the implementation of clinical trials that significantly impact ovarian cancer treatment. This award supports diverse trial designs, from early proof-of-concept studies to large-scale efficacy trials, evaluating innovative drugs, biologics, and technologies. By fostering research in this critical area, the program seeks to enhance patient outcomes and advance the understanding of ovarian cancer management.

The FY26 Breast Cancer Research Program (BCRP) Breakthrough Award Level 3 supports transformative research aimed at significant advancements in breast cancer treatment. Applicants must address key challenges outlined by the program, ensuring their proposals demonstrate potential for impactful breakthroughs. This funding mechanism, which permits small-scale clinical trials, emphasizes collaboration by requiring research teams to include two breast cancer consumer advocates and allows for a single Principal Investigator or two partnering PIs.